Authors: Salim Ben Yahia, Ines Khochtali, Haikal Neifar, Salma Gargouri,  Thameur Fattoum, Moncef Khairallah, Monastir, Tunisia


To manage diabetic macular edema (DME) with peribulbar injection of triamcinolone, known to have lower rate of ocular complications than intravitreal injection.


A single peribulbar injection of triamcinolone (40 mg) was performed. Outcome measures included changes in logMAR best-corrected visual acuity, central macular thickness (CMT), and blood glucose and glycated hemoglobin (HbA1c) levels 3 months after injection.

Effectiveness / Safety:

Visual acuity improved from 1.24 to 0.97 (P= .06) and CMT from 517 μm to 373 μm (P= .009). No significant changes in the blood levels of glucose (P= .93) and HbA1c (P= .76) were observed.

Take home message:

Peribulbar injection of triamcinolone seems to be an effective treatment for diffuse diabetic macular edema without inducing significant changes in glycemic parameters.